{"id":26030,"date":"2023-12-13T18:10:41","date_gmt":"2023-12-13T12:40:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26030"},"modified":"2024-09-17T16:59:08","modified_gmt":"2024-09-17T11:29:08","slug":"phase-3-results-support-d-vrd-in-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma","title":{"rendered":"DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>12th December 2023<\/td><\/tr>
Indications<\/td>Multiple Myeloma<\/td><\/tr>
Abstract Number<\/td>LBA1<\/td><\/tr>
Abstract type<\/td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of D-VRd followed by D-R maintenance vs VRd followed by R maintenance in patients with transplant-eligible NDMM. The findings presented at the ASH 2023 demonstrated that, at a median follow-up of 47.5 months, the 4-year progression-free survival (PFS) rate with D-VRd was 84.3% vs. 67.7% with VRd, resulting in a 58% reduction in the risk of disease progression or death with the addition of the CD38 monoclonal antibody. <\/strong>Moreover, the comprehensive response rate, including complete response or better (\u2265CR), was 87.9% for D-VRd compared to 70.1% for VRd (P <.0001). In the D-VRd group, the rates of stringent complete response (sCR) and complete response (CR) were 69.3% and 18.6%, respectively, while in the VRd group, these rates were 44.6% and 25.4%. Furthermore, the quadruplet regimen substantially enhanced the extent of response in contrast to VRd monotherapy, resulting in elevated rates of complete response or better, stringent complete response (sCR), and minimal residual disease (MRD) negativity.<\/strong><\/p>\n\n\n\n

The overall safety profile of D-VRd remained consistent with the established safety profiles of daratumumab and VRd. The most frequently occurring Grade 3\/4 hematologic and non-hematologic adverse events (AE) with D-VRd, in comparison to VRd, included neutropenia (62.1% vs. 51.0%), thrombocytopenia (29.1% vs. 17.3%), diarrhea (10.5% vs. 7.8%), pneumonia (10.5% vs. 6.1%), and febrile neutropenia (9.4% vs. 10.1%).<\/p>\n\n\n\n

Below is the expected launch year for D-RVd in both the frontline setting for patients eligible for transplantation and patients not eligible for transplantation.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

\u201cThese randomized, phase 3 results support D-VRd followed by DR maintenance as a new standard of care [SOC] for transplant-eligible patients with newly diagnosed multiple myeloma. [Additionally], 64% of patients receiving maintenance in the D-VRd group were able to discontinue daratumumab after achieving sustained MRD negativity per protocol.\u201d \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The findings from this randomized Phase III trial endorse D-VRd induction followed by DR maintenance as the emerging standard of care for individuals eligible for transplantation with newly diagnosed multiple myeloma.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 12th December 2023 Indications Multiple Myeloma Abstract Number LBA1 Abstract type Oral The PERSEUS study is being conducted in collaboration with the European Myeloma Network as a sponsor. PERSEUS is an ongoing, randomized, open-label, Phase III study comparing the efficacy and safety of D-VRd followed by D-R maintenance vs VRd followed […]<\/p>\n","protected":false},"author":6,"featured_media":26051,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,137,841,927,18921,410,16669],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26030","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-hematology","tag-multiple-myeloma","tag-multiple-myeloma-market","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nPhase 3 Results Support D-VRd in Multiple Myeloma | ASH 2023<\/title>\n<meta name=\"description\" content=\"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Vs. Vrd Alone in Multiple Myeloma Patients\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 3 Results Support D-VRd in Multiple Myeloma | ASH 2023\" \/>\n<meta property=\"og:description\" content=\"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Vs. Vrd Alone in Multiple Myeloma Patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T12:40:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:29:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Phase 3 Results Support D-VRd in Multiple Myeloma | ASH 2023","description":"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Vs. Vrd Alone in Multiple Myeloma Patients","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma","og_locale":"en_US","og_type":"article","og_title":"Phase 3 Results Support D-VRd in Multiple Myeloma | ASH 2023","og_description":"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Vs. Vrd Alone in Multiple Myeloma Patients","og_url":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-13T12:40:41+00:00","article_modified_time":"2024-09-17T11:29:08+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma","url":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma","name":"Phase 3 Results Support D-VRd in Multiple Myeloma | ASH 2023","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma.png","datePublished":"2023-12-13T12:40:41+00:00","dateModified":"2024-09-17T11:29:08+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Vs. Vrd Alone in Multiple Myeloma Patients","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-results-support-d-vrd-in-multiple-myeloma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma.png","width":1200,"height":800,"caption":"Phase 3 Results Support D-VRd"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13181035\/phase-3-results-support-d-vrd-in-multiple-myeloma-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 13, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 13, 2023 6:10 pm","modified":"Updated on Sep 17, 2024 4:59 pm"},"featured_img_caption":"Phase 3 Results Support D-VRd","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26030"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26030\/revisions"}],"predecessor-version":[{"id":29573,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26030\/revisions\/29573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26051"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26030"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26030"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}